21.23 Up +0.49 +2.36%
COMPANY ADDRESS
ACADIA PHARMACEUTICALS Inc
11085 Torreyana Road
San Diego, CA 92121
USA - Map
Phone: +1 858 558-2871
Fax: +1 858 558-2872
Website
COMPANY INFORMATION
Exchange: NASDAQ national market
Stock: ACADIA Pharmaceuticals Inc
Industry: Biotechnology
Employees: 48
DESCRIPTION
ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.
DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

Financial data in US dollars | Page generated 3:26 PM ET
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money. Learn more
SYMBOL
LAST
CHANGE
SHARES
Quotes delayed at least 15 min
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] The time is drawing near for the FOMC to release its latest policy directive. It will be done at the top of the hour; and the major indices are mixed at the bottom of the hour. Market participants are expecting the policy directive to ... More
Sponsored by: